Effective management of nausea and vomiting caused by selinesol

Selinexor is a new type of XPO1 inhibitor that is widely used to treat relapsed or refractory multiple myeloma and certain types of lymphoma. Although its mechanism is novel and its efficacy is accurate, nausea and vomiting are one of the most common adverse reactions during clinical use, significantly affecting patients' compliance and quality of life. In response to this problem, a series of clinically effective countermeasures have been summarized to reduce its interference with the patient's treatment process.

First of all, in terms of prevention, it is recommended that regular use of antiemetic drugs before taking medication is the most direct and effective strategy. Experience shows that 5-HT3 receptor antagonists such as Ondansetron or Granisetron taken orally or intravenously 30 minutes before taking the drug can help effectively relieve initial gastrointestinal reactions. This conditioning strategy has been widely used in clinical trials of selinesol treatment and has become a standard recommendation in practice.

Secondly, for persistent nausea or vomiting symptoms that have already occurred, a multi-mechanism combined anti-emetic program should be adopted for intervention. This may include NK1 receptor antagonists such as Aprepitant, or D2 receptor antagonists such as Metoclopramide. When necessary, corticosteroids such as dexamethasone combined with antiemetics can also be considered to improve the antiemetic effect, especially for complex cases in which multiple antiemetic mechanisms are involved.

In addition to pharmacological intervention, adjusting the timing and mode of selinesol administration may also improve tolerability. Some studies recommend that patients take medication after meals during the day and keep the stomach moderately saturated before and after taking the medication to reduce gastric irritation and discomfort. In addition, appropriately reducing the initial dose and gradually adjusting it to the recommended dose based on the patient's individual response is also a strategy to reduce the risk of adverse reactions, but it must be carried out strictly under the guidance of a doctor.

Reference materials:https://www.selincro.com/